Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Allogeneic hematopoietic cell transplant (allo‐HCT) provides the only potential route to long‐term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP‐MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry‐based study of BP‐MPN patients undergoing allo‐HCT. BP‐MPN patients undergoing first allo‐HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow‐up of 62 months, the estimated 3‐year overall survival (OS) was 36% (95% confidence interval [CI], 32–36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo‐HCT (HR 1.45, p < .001), whereas patients undergoing allo‐HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3‐year OS of patients undergoing allo‐HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression‐free survival (PFS). Conversely, most recent allo‐HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo‐HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo‐HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo‐HCT from mismatched related donors were associated with a higher non‐relapse mortality (HR 2.66, p = .003). In this large series of BP‐MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo‐HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.

[1]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[2]  M. Tormo,et al.  Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. , 2022, Leukemia research.

[3]  M. Heuser,et al.  Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis , 2022, Blood Advances.

[4]  P. Mazza,et al.  GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS , 2021, Transplantation and Cellular Therapy.

[5]  M. Robin,et al.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party , 2021, Leukemia.

[6]  P. Guglielmelli,et al.  Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases , 2021, American journal of hematology.

[7]  R. Chakraverty,et al.  Graft Versus Leukemia: Current Status and Future Perspectives. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Montoto,et al.  How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. , 2020, Blood advances.

[9]  H. Deeg,et al.  Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. , 2020, Blood advances.

[10]  V. Najfeld,et al.  Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. , 2020, Blood advances.

[11]  Y. Liu,et al.  Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. , 2020, Blood advances.

[12]  R. Levine,et al.  Leukemia secondary to myeloproliferative neoplasms , 2020 .

[13]  S. Koschmieder,et al.  Role of inflammation in the biology of myeloproliferative neoplasms. , 2020, Blood reviews.

[14]  E. Clappier,et al.  Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation? , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  N. Kröger,et al.  Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia , 2019, British journal of haematology.

[16]  O. Odenike.  How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. , 2018, Blood.

[17]  M. Minden,et al.  The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. , 2018, Blood advances.

[18]  A. Tefferi,et al.  Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis , 2018, Blood Cancer Journal.

[19]  P. Guglielmelli,et al.  Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts , 2018, Leukemia.

[20]  T. Barbui,et al.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.

[21]  W. Vainchenker,et al.  Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. , 2017, Blood.

[22]  Alan M. Miller,et al.  Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  M. Nørgaard,et al.  Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Daniel Wolff,et al.  Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .

[26]  James R Carpenter,et al.  Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model , 2012, Statistical methods in medical research.

[27]  M. Robin,et al.  Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) , 2014, Bone Marrow Transplantation.

[28]  N. Kröger,et al.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  Francisco Cervantes,et al.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.

[30]  S. Solomon,et al.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Komatsu.  [Myeloproliferative neoplasms]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[32]  O. Abdel-Wahab,et al.  Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. , 2012, Leukemia research.

[33]  C. Craddock,et al.  Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia , 2011, Leukemia.

[34]  M. Sorror,et al.  Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.

[35]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  J. Wagner,et al.  Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.